Moderna Narrows Losses as Cost-Cutting Strategy Begins to Stabilize Financial Outlook
Image
SHERIDAN, WYOMING - November 10, 2025 - Moderna's latest quarterly report signals cautious optimism for the biotech sector, as the company's cost-reduction campaign shows measurable progress in curbing financial losses. The mRNA innovator reported a $200 million net loss for the third quarter-its fourth consecutive decline-but markedly smaller than previous quarters. Executives emphasized that the company is regaining operational balance through disciplined expense management and diversification beyond COVID-19 vaccines.